Sun Pharma delivered strong Q3 FY26 results with gross sales up 15.1% year-on-year to Rs 15,469.1 Cr.

Nine-month gross sales rose 11.3% to Rs 43,660.4 Cr.

India Formulations led growth, up 16.2%, followed by Emerging Markets at 28.3%, and US Formulations at 6.2%. Adjusted Net Profit for Q3 increased 9.9% to Rs 3,536.7 Cr, while 9-month adjusted net profit rose 6.1% to Rs 9,650.8 Cr.

The company is focused on sustainable long-term growth by enhancing its innovative and complex product portfolio and optimizing costs.

Key strategies include expanding its innovative medicines business, boosting productivity in the US, and maintaining leadership in India.

Recent developments include completing the Taro merger and acquiring Checkpoint Therapeutics, strengthening its oncology and dermatology franchises.

Its Innovative Medicines portfolio now accounts for 20% of sales and continues to grow.

Adjusted EPS for Q3 was Rs 14.7, up 9.9%. R&D investment stood at 6.2% of sales in FY25. Management targets mid to high single-digit consolidated topline growth for FY26, emphasizing sustainable and profitable growth with improved return ratios.